National Cancer Survivors Day

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 17 No 7
Volume 17
Issue 7

CHICAGO-Sunday, June 1 marked the 15th annual Cancer Survivors’ Celebration and Walk, sponsored by the Robert H. Lurie Cancer Center of Northwestern University as part of National Cancer Survivors Day. More than 800 cancer survivors participated in the walk (see photograph).

CHICAGO-Sunday, June 1 marked the 15th annual Cancer Survivors’ Celebration and Walk, sponsored by the Robert H. Lurie Cancer Center of Northwestern University as part of National Cancer Survivors  Day. More than 800 cancer survivors participated in the walk (see photograph).

Articles in this issue
National Cancer Survivors Day
New Indication for Velcade in Previously Untreated Myeloma
Risk Factors for Mantle Cell Lymphoma Identified
RAS Mutations Enhance Chemotherapy in AML
Antidiabetic Agent Metformin May Boost pCRs in Breast Ca
Eisai Seeks Full FDA Approval for Ontak for CTCL
Symptom Screen Plus CA125 Detects Early Ovarian Ca
Cisplatin Linked to Cardiac Complications in Testicular Ca Patients
Updated X-ACT Study Results Presented
ThromboGenics and BioInvent Announce Alliance with Roche
Gene Signature Identifies Low-Risk Patients in MAGE-A3 Trial
p110-Beta Drives Cancer Growth When PTEN is Inhibited, Animal Study Shows
Proton beam RT not exempt from evidence-based medicine
Investigational Agents May be Effective for Resistant GIST
Coverage vs Cost-Cutting: A look Inside the Obama and McCain Healthcare Plans
Recent Videos
Thomas Powles, MBBS, MRCP, MD, highlighted fatigue, nausea, and peripheral neuropathy as toxicities observed with enfortumab vedotin plus pembrolizumab.
According to Megan Mullins, PhD, MPH, challenging cultural norms surrounding death and dying may reduce the receipt of low-value end-of-life cancer care.
Earlier and more frequent talks about disabling ICDs with patients receiving end-of-life care and their families may help avoid excessive pain.
3 experts in this video
3 experts in this video
Large international meetings may facilitate conversations regarding disparities of care outside of high-income countries.
6 experts are featured in this series.
6 experts are featured in this series.
Related Content
Data presented at 2025 ASCO GU reinforce the use of agents like nivolumab, cabozantinib, and darolutamide across different genitourinary malignancies.

Top 5 Takeaways for Genitourinary Cancer Care From 2025 ASCO GU

Russ Conroy
February 21st 2025
Article

Data presented at 2025 ASCO GU reinforce the use of agents like nivolumab, cabozantinib, and darolutamide across different genitourinary malignancies.

Clinicians outline the significance of the MZL Workshop, where a gathering of international experts in the field discussed updates in the disease state.

Highlighting Insights From the Marginal Zone Lymphoma Workshop

Thomas Habermann, MD;Julie M. Vose, MD, MBA;James R. Cerhan, MD, PhD;Alexandar Tzankov, MD;Andrew D. Zelenetz, MD, PhD
February 17th 2025
Podcast

Clinicians outline the significance of the MZL Workshop, where a gathering of international experts in the field discussed updates in the disease state.

The Potential for Improved Processes, Outcomes, and Economics of Health Care

The Potential for Improved Processes, Outcomes, and Economics of Health Care

Nora Janjan, MD, MPSA, MBA
February 21st 2025
Article

DOGE hopes to solve rampant inefficiencies in US healthcare that contribute to unsustainable costs and a broken system by cutting spending and administrative waste.

Experts from Washington University in St. Louis discuss trial results and infusion-related reaction management for amivantamab in EGFR-mutated NSCLC.

Navigating Management and Dosing Considerations for Amivantamab in NSCLC

Daniel Morgensztern, MD;Mary Ellen Flanagan, NP ;Janelle Mann, PharmD, BCOP
February 10th 2025
Podcast

Experts from Washington University in St. Louis discuss trial results and infusion-related reaction management for amivantamab in EGFR-mutated NSCLC.

Results from the phase 1/2a SeCuRE trial support the FDA decision for patients with metastatic castration-resistant prostate cancer.

Cu-67 SAR-bisPSMA Granted Fast Track Designation for Metastatic CRPC

Roman Fabbricatore
February 20th 2025
Article

Results from the phase 1/2a SeCuRE trial support the FDA decision for patients with metastatic castration-resistant prostate cancer.

Investigators will assess treatment with petosemtamab among patients with PD-L1–positive HNSCC in the phase 3 LiGeR-HN1 and LiGeR-HN2 trials.

Petosemtamab Combo Earns Breakthrough Therapy Status in PD-L1+ HNSCC

Russ Conroy
February 20th 2025
Article

Investigators will assess treatment with petosemtamab among patients with PD-L1–positive HNSCC in the phase 3 LiGeR-HN1 and LiGeR-HN2 trials.